Karyopharm Therapeutics Inc.
KPTI · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 10, 2026 | — | 33.12M | — | -1.25 | — |
| 2026 Q1 | May 14, 2026 | 35.07M | 31.40M | -1.24 | -1.45 | +0.56% |
| 2025 Q4 | February 12, 2026 | 34.08M | 35.10M | -2.23 | -2.26 | +21.30% |
| 2025 Q3 | November 3, 2025 | 44.04M | 42.06M | -3.82 | -3.30 | +4.66% |
| 2025 Q2 | August 11, 2025 | 37.93M | 39.56M | -4.32 | -3.80 | -4.31% |
| 2025 Q1 | May 12, 2025 | 30.02M | 35.12M | -2.77 | -4.21 | — |
| 2024 Q4 | February 19, 2025 | 30.54M | 37.83M | -54.00 | -3.93 | -4.76% |
| 2024 Q3 | November 5, 2024 | 38.78M | 38.20M | -3.90 | -3.97 | -9.36% |
| 2024 Q2 | August 6, 2024 | 42.79M | 36.18M | -3.00 | -4.35 | -3.56% |
| 2024 Q1 | May 8, 2024 | 33.13M | 34.47M | -4.80 | -4.92 | -7.27% |
| 2023 Q4 | February 29, 2024 | 33.75M | 35.40M | -5.40 | -4.38 | -12.78% |
| 2023 Q3 | November 2, 2023 | 36.01M | 37.28M | -4.50 | -4.24 | -3.17% |
| 2023 Q2 | August 2, 2023 | 37.58M | 36.01M | -4.35 | -5.13 | -0.56% |
| 2023 Q1 | May 4, 2023 | 38.70M | 36.60M | -4.50 | -5.07 | -24.32% |
| 2022 Q4 | February 15, 2023 | 33.58M | 34.43M | -6.45 | -5.14 | +10.24% |
| 2022 Q3 | November 3, 2022 | 36.15M | 34.83M | -6.75 | -8.43 | -4.62% |